Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Intangibles (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Intangibles for 6 consecutive years, with $15.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Change in Intangibles rose 50.0% to $15.0 million in Q1 2025 year-over-year; TTM through Dec 2025 was $15.0 million, a 15.38% increase, with the full-year FY2025 number at $15.0 million, up 15.38% from a year prior.
  • Change in Intangibles was $15.0 million for Q1 2025 at Ultragenyx Pharmaceutical, up from $500000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $30.0 million in Q1 2022 to a low of $500000.0 in Q4 2023.
  • A 4-year average of $8.7 million and a median of $2.5 million in 2023 define the central range for Change in Intangibles.
  • Peak YoY movement for Change in Intangibles: changed 0.0% in 2024, then soared 50.0% in 2025.
  • Ultragenyx Pharmaceutical's Change in Intangibles stood at $30.0 million in 2022, then tumbled by 98.33% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then soared by 2900.0% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Intangibles are $15.0 million (Q1 2025), $500000.0 (Q4 2024), and $2.5 million (Q2 2024).